| Literature DB >> 29930891 |
Karl Theo von der Trenck1,2, Rainer Konietzka3, Annegret Biegel-Engler3, Jan Brodsky4, Andrea Hädicke5, Arnold Quadflieg6, Rudolf Stockerl7, Thorsten Stahl8.
Abstract
BACKGROUND: Per- and polyfluorinated chemicals (PFC) do not occur naturally in the environment and are, therefore, of anthropogenic origin. As a consequence of their wide range of everyday applications and their extreme persistence in the environment, PFC have become ubiquitous in nature and can, therefore, be detected in groundwater as well as in many other environmental matrices. The German States' Water and Soil Consortia have compiled 'significance thresholds' (GFS) to assess groundwater contaminated with PFC. The GFS serve as criteria for the decision whether actions to remediate polluted groundwater are necessary. Thirteen of these PFC had been detected in groundwater at levels above their limit of quantitation and were assigned first priority.Entities:
Keywords: Chemical risk assessment; Groundwater; PFAS; PFC; Thresholds
Year: 2018 PMID: 29930891 PMCID: PMC5992233 DOI: 10.1186/s12302-018-0142-4
Source DB: PubMed Journal: Environ Sci Eur ISSN: 2190-4715 Impact factor: 5.893
Findings of PFC in aqueous samples
| Matrix | Number of measurements (n) | Substancesa | Concentration rangeb (ng/L) | Literature |
|---|---|---|---|---|
| Effluent/landfill leachate | 24 | PFBA | < LOQ—45,917 | [ |
| Surface water | 22 | PFBA | < LOQ—143 | [ |
| Surface water | 38 | PFBA | < LOQ—3.0 | [ |
| Ground water | 2057 | PFBA | < LOQ—52.0 | [ |
| Drinking water | 26 | PFBA | < LOQ—4.4 | [ |
LOQ limit of quantitation
aThe substances listed were detected in amounts above the LOQ. Abbreviations cf. Tables 2 and 3
bThese values represent the range between the lowest and highest detected amounts of the respective substances
First priority PFC, listed in DIN 38407-42 [18]; except PFHpS, H4PFOS, PFOSA
| No. | CAS-no. | Name | Abbreviation |
|---|---|---|---|
| 1 | 375-22-4 | Perfluorobutanoic acid | PFBA |
| 2 | 2706-90-3 | Perfluoropentanoic acid | PFPeA, PFPA |
| 3 | 307-24-4 | Perfluorohexanoic acid | PFHxA |
| 4 | 375-85-9 | Perfluoroheptanoic acid | PFHpA |
| 5 | 335-67-1 | Perfluorooctanoic acid | PFOA |
| 6 | 375-95-1 | Perfluorononanoic acid | PFNA |
| 7 | 335-76-2 | Perfluorodecanoic acid | PFDA |
| 8 | 375-73-5 | Perfluorobutanesulfonic acid | PFBS |
| 9 | 355-46-4 | Perfluorohexanesulfonic ac | PFHxS |
| 10 | 375-92-8 | Perfluoroheptanesulfonic acid | PFHpS |
| 11 | 1763-23-1 | Perfluorooctanesulfonic acid | PFOS |
| 12 | 27619-97-2; 425670-75-3 (Anion) | 1 | H4PFOS, 6:2 FTSA |
| 13 | 754-91-6 | Perfluorooctanesulfonamide | PFOSA or FOSA |
Second priority PFC
| No. | CAS-no. | Name | Abbreviation |
|---|---|---|---|
| 14 | 2058-94-8 | Perfluoroundecanoic acid | PFUnA, PFUdA, PFUndA+D53 |
| 15 | 307-55-1 | Perfluorododecanoic acid | PFDoA |
| 16 | 72629-94-8 | Perfluorotridecanoic acid | PFTrA, PFTrdA |
| 17 | 376-06-7 | Perfluorotetradecanoic acid | PFTeA, PFTetA |
| 18 | 335-77-3 | Perfluorodecanesulfonic acid | PFDS, PFDeS |
| 19 | 34598-33-9 | 2 | H4PFUnA |
| 20 | 1546-95-8 | 7 | HPFHpA |
| 21 | 34598-33-9 | 2 | 8:2 FTA, 8:2 FTCA, n-8:2FTCA, H2PFDA |
| 22 | 757124-72-4; 414911-30-1 (Anion) | 1 | 4:2 FTSA, H4PFHxS |
| 23 | 39108-34-4; 481071-78-7 (Anion) | 1 | 8:2 FTSA, H4PFDS |
Fig. 1Scheme to derive significance threshold (GFS) values [62]
Overview of the rationales for PFC with GFS
| No. | Abbreviation | Pivotal study | Effect at LOAEL | Point of departure (mg/kg day) | Factor elimination t1/2 human/animal | Assessment factors | Human equivalent dose (μg/kg day) | Concentration in DW (µg/L) | GFS (μg/L) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | PFBA | 90 days oral, rat ♂ [ | Hepatocellular hypertrophy; thyroid hyperplasia/hypertrophy | 6 | 8 | 10 | 3–7.5 | 10–52a | 10 |
| 3 | PFHxA | 104 weeks oral, rat ♂ ♀ [ | Lower urine pH, kidney histology | 15 | 327 | – | 1.84 | 6.42 | 6 |
| 5 | PFOA | Human [ | Reduced protection against A/H3N2-virus provided by influenza vaccination [ | Serum concentration at steady state: 90 µg/L human serum, converted to human equivalent dose | 0.02037 | 0.071 | 0.1c | ||
| 6 | PFNA | 2 generation oral, rat ♂ ♀ [ | Microscopic liver lesions; hepatocellular hypertrophy | 0.025 | 50 | 3* | 0.0167 | 0.0583 | 0.06 |
| 8 | PFBS | 90 days oral, rat ♂ [ | Reduced erythrocytes, hemoglobin and hematocrit | 60 | 146 | 10 | 1.64 | 5.74 | 6 |
| 9 | PFHxS | 42 days oral, rat ♂ [ | Raised liver weight, hepatocellular hypertrophy; thyroid hyperplasia; reduced hematocrit | 1 | 90 | 15 | 0.03 | 0.1037 | 0.1b |
| 11 | PFOS | 2 years oral rat ♂ [ | Hepatocellular hypertrophy [ | Serum concentration at steady state: 20 µg/L human serum as middle from the pivotal studies [ | 0.0286 | 0.1 | 0.1 | ||
Assessment factors for: 1. duration of the study, 2. inter-species toxico-dynamic differences, 3. intra-species differences, * extrapolation to NOAEL, ** special risks such as carcinogenicity, genotoxicity, etc. Under the line: product of factors
NK natural killer cells, IgM immunoglobulin M
aDrinking water allocation 10–20%
bSecured by identical HRIV
cValue rounded because of mixed exposure with PFOS under field conditions
GFS for PFC [17, 38] of first priority (rationale for prioritization see section “List of contaminants selected”)
| No. | Name, abbreviation (CAS no.) | GFS (μg/L) | Basis (μg/L) | |
|---|---|---|---|---|
| Human health | PNEC | |||
| 1 | Perfluorobutyric acid, PFBA (375-22-4) | 10 | 10 | 1260 |
| 2 | Perfluoropentanoic acid, PFPeA (2706-90-3) | – | − (HRIV: 3.0) | 320 |
| 3 | Perfluorohexanoic acid, PFHxA (307-24-4) | 6 | 6 | 1000 |
| 4 | Perfluoroheptanoic acid, PFHpA (375-85-9) | – | − (HRIV: 0.3) | – |
| 5 | Perfluoroctanoic acid, PFOA (335-67-1) | 0.1 | 0.1 | 570 |
| 6 | Perfluorononanoic acid, PFNA (375-95-1) | 0.06 | 0.06 | 8 |
| 7 | Perfluorodecanoic acid, PFDA (335-76-2) | – | − (HRIV: 0.1) | 10 |
| 8 | Perfluorobutanesulfonic acid, PFBS (375-73-5) | 6 | 6 | 3700 |
| 9 | Perfluorohexanesulfonic acid, PFHxS (355-46-4) | 0.1 | 0.1 | 250 |
| 10 | Perfluoroheptanesulfonic acid, PFHpS (375-92-8) | – | − (HRIV: 0.3) | – |
| 11 | Perfluorooctanesulfonic acid, PFOS (1763-23-1) | 0.1 | 0.1 | 0.23 |
| 12 | H4-Polyfluorooctanesulfonic acid, H4PFOS (27619-97-2) | – | − (HRIV: 0.1) | 870 |
| 13 | Perfluorooctanesulfonamide, PFOSA (754-91-6) | – | − (HRIV: 0.1) | – |
The HRIV for non-assessable substances is explained in sections “Substances insufficiently characterized” and “Uncertainty analysis” as well as in LAWA [62]